Protaryx Medical (Baltimore, MD) has raised $8.3 million to develop a first-in-class device for precision transseptal access to the left atrium during structural heart and catheter ablation procedures. The funding includes non-dilutive grants and a seed round totaling $3.2 million and a $5.1 million Series A financing led by Ajax Health and participation from the University of Maryland (UM) Ventures. The device is designed for use in catheter-based procedures such as mitral valve repair and replacement, left atrial appendage closure and catheter ablation to treat cardiac arrhythmias. Read more.